Evotec

Traded on the St. Petersburg Stock Exchange
Evotec is a drug discovery and development company. It operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. The company was founded in 1993 and is headquartered in Hamburg, Germany.
Evotec stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Evotec balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, €
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Evotec cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Evotec multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Evotec profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Evotec assets
Evotec cash flows

Evotec shares

TickerNameTypeNominal valueISINPrice
EVT:GREvotecCommon share-DE0005664809€13.41
Evotec news
05.07.2022
Evotec has completed the acquisition of Rigenerand for €23 million. The company owns the cell therapy manufacturing facility for cGMP standards.
Source: {source} pictogram evotec.com
Pictogram next
30.05.2022
Evotec is acquiring Rigenerand Srl for €23 million. The company owns a cell therapy manufacturing facility in accordance with cGMP standards. The closing date of the deal is not specified.
Source: {source} pictogram evotec.com
Pictogram next
11.05.2022
Evotec's IFRS loss for 3 months of 2022 was €73.242 million, compared to a profit of €52.702 million in the previous year. Revenue increased by 23.7% to €164.672 million compared to €133.085 million in the previous year.
Source: {source} pictogram evotec.com
Pictogram next
11.11.2021
Evotec' IFRS net profit for 9M 2021 amounted to €246,988 million, up 42.2 times from €5,849 million in the previous year. Revenue increased by 19.6% to €430.963 million compared to €360.414 million a year earlier.
Source: {source} pictogram evotec.com
Pictogram next
All Evotec news
General information
Company nameEvotec
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressEssener Bogen 7 Hamburg, 22419 Germany
Mailing addressEssener Bogen 7 Hamburg, 22419 Germany
Websitewww.evotec.com